---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-037051"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:19:43.372171+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025

## Summary
- Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.
- Cash, cash equivalents, restricted cash and marketable securities of $78.1M as of June 30, 2024.
- Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo; top-line results expected mid-2025.
- Phase 1a SAD/MAD trial of VYN202 ongoing; SAD data in Q3 2024, MAD data in Q4 2024.
- Appointed Dr. Subhashis Banerjee as SVP of Clinical Development; previously at Bristol Myers Squibb.

## SEC filing metadata
- accession: 0001628280-24-037051
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828024037051/0001628280-24-037051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828024037051/mnlo-20240814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-037051
- JSON: https://secwatch.observer/filing/0001628280-24-037051.json
- Plain text: https://secwatch.observer/filing/0001628280-24-037051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.